Skip to main content
. Author manuscript; available in PMC: 2012 May 1.
Published in final edited form as: J Hepatol. 2010 Oct 26;54(5):994–1001. doi: 10.1016/j.jhep.2010.08.034

Fig. 1. Hepatic p62 overexpression.

Fig. 1

(A) Generation of p62 transgenic mice. No expression of p62 mRNA under TRE-CMV promotor control (upper panel). Liver-specific expression of p62 mRNA in double-positive p62+/LT2+ mice (middle panel). Application of doxycycline inhibits transgene expression (lower panel). TRE-CMVmin: transrepressor responsive element cytomegalovirus; tTA: tetracycline transactivator; LAP: liver enriched activator protein; dox: doxycycline (B) p62 expression in different mouse organs. The Northern Blot detects the 2.0 kb band of p62 mRNA only in livers of p62 transgenic mice. (C) p62 mRNA expression after doxycycline (dox) administration. (D) Hepatic p62 mRNA expression (n=14/2.5 weeks, n=21/5 weeks, and n=8/10 weeks). (E) tTA expression in LT2+ mice (n=7/2.5 weeks, 12/5 weeks, and 8/10 weeks). (F) p62 immunohistochemistry.